Skip to content

Assembly Biosciences, Inc.: 10-Q filed 2012-08-09

What Assembly Biosciences, Inc. reported in its quarterly report filed 2012-08-09 (fiscal Q2 2012): 22 published measures, 67 facts as tagged in accession 0001144204-12-044116.

This filing

Form
10-Q (quarterly report)
Filed
2012-08-09
Fiscal period
fiscal Q2 2012
Accession
0001144204-12-044116 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Assembly Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-06-3029,010,340USD
At 2011-12-3137,045,781USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-06-3025,618,502USD
At 2011-12-3134,532,707USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-06-3028,843,880USD
At 2011-12-3136,975,434USD
At 2011-06-3011,368,535USD
At 2010-12-3114,571,055USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-7,470,048USD91
2012-01-01 to 2012-06-30-15,643,924USD182
2005-10-07 to 2012-06-30-83,173,008USD2459
2011-04-01 to 2011-06-30-6,961,511USD91
2011-01-01 to 2011-06-30-9,683,991USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-13,025,130USD182
2005-10-07 to 2012-06-30-53,463,430USD2459
2011-01-01 to 2011-06-30-4,666,935USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-06-303,240USD182
2005-10-07 to 2012-06-3042,464USD2459
2011-01-01 to 2011-06-3011,964USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-06-304,896,816USD182
2005-10-07 to 2012-06-3082,349,774USD2459
2011-01-01 to 2011-06-301,476,379USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-3,240USD182
2005-10-07 to 2012-06-30-42,464USD2459
2011-01-01 to 2011-06-30-11,964USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-06-309,375USD
At 2011-12-318,218USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-06-301,540,553USD182
2005-10-07 to 2012-06-307,480,824USD2459
2011-01-01 to 2011-06-301,555,344USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-7,478,306USD91
2012-01-01 to 2012-06-30-15,668,363USD182
2005-10-07 to 2012-06-30-69,442,674USD2459
2011-04-01 to 2011-06-30-6,901,571USD91
2011-01-01 to 2011-06-30-9,568,364USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-06-3029,000,965USD
At 2011-12-3137,037,563USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2005-10-07 to 2012-06-3013,850,826USD2459
2011-04-01 to 2011-06-3065,907USD91
2011-01-01 to 2011-06-30135,084USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-06-303,391,838USD
At 2011-12-312,513,074USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-06-303,157,838USD
At 2011-12-312,342,074USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-04-01 to 2012-06-306,161,924USD91
2012-01-01 to 2012-06-3012,584,650USD182
2005-10-07 to 2012-06-3052,113,893USD2459
2011-04-01 to 2011-06-303,099,582USD91
2011-01-01 to 2011-06-304,070,344USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-06-3012,922,730shares
At 2011-12-3112,406,406shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-06-30108,778,587USD
At 2011-12-31102,049,385USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-06-30234,000USD
At 2011-12-31171,000USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-04-01 to 2012-06-301,316,382USD91
2012-01-01 to 2012-06-303,083,713USD182
2005-10-07 to 2012-06-3017,328,781USD2459
2011-04-01 to 2011-06-303,801,989USD91
2011-01-01 to 2011-06-305,498,020USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-01-01 to 2012-06-302,083USD182
2005-10-07 to 2012-06-3033,090USD2459
2011-01-01 to 2011-06-301,752USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-05-08 to 2012-06-304,166,000USD54
2012-01-01 to 2012-06-304,166,494USD182
2005-10-07 to 2012-06-3069,339,661USD2459
2011-01-01 to 2011-06-302,420,775USD181

Inspect the source

Entity
Assembly Biosciences, Inc. / CIK 0001426800
Captured
2026-09-20T08:03:55.156Z
SEC response SHA-256
f87ee3d44f43bd73d30c280e8d97b2de4bcc4d8a35b03fbebb0e715c83069335

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001426800.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))